Bariatric and Metabolic CPD Webinar

Obesity Crisis Meets Treatment Shifts

Ireland stands on the brink of an obesity epidemic unmatched in Europe, with 60% of adults already overweight or obese and projections warning of the country claiming the continent's top spot by 2030. This surge drives sharp rises in type 2 diabetes, cardiovascular disease, certain cancers, and other comorbidities, imposing heavy burdens on individuals and the health service alike.

Bariatric and metabolic surgery remains the most effective intervention for severe obesity, achieving 25-35% sustained total body weight loss and high rates of diabetes remission, far outpacing lifestyle or medication-only approaches. Yet public provision lags badly: waiting lists often exceed four years, with thousands queued for assessment and surgery in centres like St Vincent's and Galway, even as efforts aim to scale capacity toward 1,200 annual cases.

The arrival of potent GLP-1 receptor agonists has transformed the landscape, providing 10-15% weight loss for many but requiring indefinite treatment to maintain benefits, with rebound common upon stopping. This introduces a key tension—medications suit broader BMI ranges and less severe cases, or those unfit for surgery, but surgery delivers superior durability and cost savings over time, estimated at €15,000 per patient in a decade in some European analyses.

Regulatory attention has intensified: European bodies issued 2025 consensus guidelines on medical tourism, stressing accredited centres and approved procedures to curb complications from unregulated overseas surgery, a growing recourse for Irish patients frustrated by delays. Meanwhile, private initiatives expand, and Northern Ireland's new obesity service launches in 2026, potentially incorporating surgery later.

These shifts demand updated awareness among GPs, who serve as gatekeepers for referrals and integrated care amid evolving guidelines, pharmacological options, and service gaps.